Evaluation of Brain natriuretic peptide in premature heart contraction patients

The current study was designed to study biomarkers of premature atrial and ventricular contraction by using brain natriuretic peptide (BNP). The study was performed on patients' clinics and private laboratories in AL-Najaf Governorate / Iraq from August 15\8\2024, to January 15\1\2025.
The total number was ninety (90) participants, including sixty (60) patients with premature heart contractions and thirty (30) was the healthy control group. Patients were subdivided into several subdivisions according to age, type of premature heart contraction (atrial and ventricular), diagnosis (treated or new diagnosis), duration of disease, hypertension, and body mass index group. The present results revealed a signification increase (P<0.05) in brain natriuretic peptide in patients compared with the control group. Male patients significantly increase (P<0.05) than female patients. The current results also indicate that older age, 60-69 years, was significantly increased (P<0.05) in comparison with ventricular patients.  A new diagnosis in patients was a highly significant increase (P<0.05) than treated patients. The present study also indicated that the hypertensive patient group showed a highly significant increase (P<0.05) than the normotensive group. Duration of diseases (1 weak-1 month) in patients’ groups was highly significant (P<0.05) than (1-5) years and >5 years.
According to body mass index obese patients’ group was significantly higher (P<0.05) than the overweight and normal weight groups. The present study concluded that brain natriuretic peptide was a new biomarker in both atrial and ventricular premature contraction and can be used for diagnosing or predicting this disease to prevent any future complications.